Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Incyte (INCY)

NASDAQ: INCY · Biotechnology · Wilmington, DE

Our rating: Positive

Positive reaffirmed at $120.39, moderate conviction, October 30, 2026.

Breaks if: The Positive call flips Cautious if reported revenue growth comes in below 8% for two consecutive annual periods — at that pace, an 18.8x earnings multiple would be genuinely difficult to justify. On price, a drawdown of 22% or more from today's $120.39 (below roughly $94) within the next twelve months, absent a material positive fundamental development, would indicate the market is pricing in risk not yet visible in the company's reported figures.

Key figures

Market value$23.4B
Revenue, last 12 months$6.0B
Net income, last 12 months$403M
Free cash flow, last 12 monthsn/a
Price to earnings57.9×
Free cash flow yieldn/a
Dividend yield0.0%
Operating margin10.4%
Return on equity7.8%
Beta to the S&P 5000.52
Volatility, annualized33.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.6B14.0%$-3.86n/a
June 30, 2026$1.7B37.7%$2.81n/a
March 31, 2026$1.3B20.9%$1.47n/a
December 31, 2025$1.5B27.8%$1.46n/a
September 30, 2025$1.4B20.0%$2.11n/a
June 30, 2025$1.2B16.5%$2.04n/a
March 31, 2025$1.1B19.5%$0.80n/a
December 31, 2024$1.2B16.3%$0.95n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

30 ledger entries and 24 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.